Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LL4Y
|
|||
| Drug Name |
TAK-931
|
|||
| Synonyms |
XGVXKJKTISMIOW-ZDUSSCGKSA-N; UNII-LST350G3XU; LST350G3XU; 1330782-76-7; SCHEMBL19410618; SCHEMBL12459022; EX-A2702; HY-100888; CS-0020550; Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-; 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Takeda Oncology Deerfield, IL
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H19N5OS
|
|||
| Canonical SMILES |
CC1=C(C=NN1)C2=CC3=C(S2)C(=O)NC(=N3)C4CC5CCN4CC5
|
|||
| InChI |
1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1
|
|||
| InChIKey |
XGVXKJKTISMIOW-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 1330782-76-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CDC7-related kinase (CDC7) | Target Info | Inhibitor | [1] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.